The U.S. Food and Drug Administration (FDA) has approved a prefilled syringe presentation of GSK plc’s SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster). The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration. The approval of the new presentation is based on data demonstrating technical comparability between the new and existing vaccine presentation. Consistent ...